Showing posts with label Attack. Show all posts
Showing posts with label Attack. Show all posts

Monday, 19 August 2013

Mathematical model makes defensible estimates of how scenarios might play out if anthrax were released in a terrorist attack

Main Category: Bio-terrorism / Terrorism
Also Included In: Public Health
Article Date: 19 Aug 2013 - 1:00 PDT Current ratings for:
Mathematical model makes defensible estimates of how scenarios might play out if anthrax were released in a terrorist attack
not yet rated5 stars

If terrorists targeted the United States with an anthrax attack, health care providers and policy makers would need key information - such as knowing the likelihood of an individual becoming infected, how many cases to expect and in what pattern, and how long to give antibiotics - to protect people from the deadly bacteria.

Those questions gained urgency when anthrax-laced letters killed five people and infected 17 others in the wake of the terror attacks of September 2001. Now, using information from prior animal studies and data from a deadly anthrax exposure accident in Russia in the late 1970s, University of Utah and George E. Wahlen Department of Veterans Affairs Medical Center researchers have developed a mathematical model to help answer critical questions and guide the response to a large-scale anthrax exposure.

In a study in PLOS Pathogens online, the researchers use their model to estimate that for an individual to have a 50 percent chance of becoming infected with anthrax (known as ID50), he or she would have to inhale 11,000 spores of the bacteria. A 10 percent chance of being infected would require inhaling 1,700 spores and a 1 percent chance of infection would occur by inhaling 160 spores. The researchers also found that at ID50, the median time for anthrax symptoms to appear is 9.9 days and that the optimal time to take antibiotics is 60 days.

"Anthrax is a well-studied disease and experimental animal data exist, but there is no real good information on dose response for the disease in humans," says Adi V. Gundlapalli, M.D., Ph.D., an infectious diseases specialist and epidemiologist, associate professor of internal medicine at the U of U School of Medicine and staff physician at the Salt Lake City George E. Wahlen Department of Veterans Affairs Medical Center. "We don't want to be overly fearful, but we need to be prepared in the event of a bioterrorism attack with anthrax."

Although studies with animals at other institutions have looked at anthrax, the data are limited and usually involved vaccine testing and not exposure amounts for infection. Gleaning information from accidental exposures in isolated cases is difficult and not often helpful. So, Toth and Gundlapalli gathered what useful information from animal studies reported in the medical literature and then combined it with data from an accidental exposure at a Soviet Union bioterrorism plant that occurred in the city of Sverdlovsk, Russia, in 1979.

Gundlapalli, who as a postdoctoral fellow at the U of U helped build a bioterrorism surveillance system for the 2002 Winter Olympics in Salt Lake City, and Damon J.A. Toth, Ph.D., a mathematician and assistant professor of internal medicine at the U of U, are co-first authors on the study.

Anthrax is found on the skin of dead animals and its spores can live thousands of years. People can become infected when they are in close proximity to anthrax, such as a farmworker who might be exposed to a dead animal and inhales spores of the bacteria. But it also can be manufactured in laboratories and spread in other ways, such as when people opened letters containing anthrax or when the spores are put into an aerosol and dispersed over large areas by wind currents.

Previous studies at other institutions had provided widely varying estimates of the chance of becoming infected with anthrax with low dose exposure. For example, one model based on animal data estimated a 1 percent chance of becoming infected from inhaling one spore, while another study estimated that healthy humans would have virtually no chance of becoming infected after inhaling up to 600 spores. But analyzing the results from a better documented, non-human primate study at another institution, in combination with a carefully constructed mathematical model appropriate for humans, Toth estimated that the number of spores required for a 1 percent chance of infection is 160. These estimates were derived by developing and refining a competing-risks model in which the inhaled bacteria is trying to set up an infection in the lungs and the human body is trying to expel or control the bacteria. Toth then used available experimental animal data to optimize the working of the model to produce results that matched the timing of cases at Sverdlovsk.

"Our study, for the first time, takes all the best data and modeling techniques available on dose response and evaluates them critically," Toth says. "No one study satisfied all our criteria to be the best model, so we refined the available information to develop our model."

"When the Institute of Medicine was asked to look at the effectiveness and costs of different strategies to respond to an anthrax in 2012, the Committee identified a critical need for accurate information on the time from exposure until people became ill and how this would change depending on the dose," said Andrew Pavia, M.D., professor and chief of pediatric infectious diseases at the University of Utah and a member of the IOM committee that wrote the report, "Prepositioning antibiotics for Anthrax," and a consultant to CDC on anthrax. "The time between exposure and when symptoms develop is the most effective time to administer antibiotics to prevent illness. This study adds a thoughtful approach to using all of the available data to improve these estimates, but considerable uncertainty will remain." Pavia was not involved in the study

Along with existing animal studies, data gathered from the accident at Sverdlovsk proved invaluable. Up to 100 people died when a filter was accidently left off a piece of equipment at a plant that was developing anthrax as a bioterrorism weapon. Spores of the bacteria were released into the air near the town of Sverdlovsk. The Soviets eventually let outside experts in to study the accident. From publicly available accounts, despite limited records and a substantial delay before the investigation, it would appear that scientists were able to estimate when the release happened, plot where people were in the surrounding area when it occurred and then look at weather records to identify wind currents. With that information, they plotted how the spores were scattered in relation to people who became infected.

The timing and geographic pattern of the best documented cases from Sverdlovsk were consistent with both the shape of the dose-response curve and the distribution of incubation periods produced by the new model. The model also sheds light on how long antibiotics should be given after an exposure to decrease the chances of infection. The model's predictions match so well with publicly available Sverdlovsk data that Gundlapalli and Toth believe they can use the model to reasonably estimate how exposures to anthrax would unfold, especially at low doses of the bacteria.

"By combining the data from Sverdlovsk and prior studies, we can make defensible estimates on how scenarios might play out if anthrax were released in a terrorist attack," Gundlapalli says. "How many cases could we expect? When would be expect to see the cases? How long should we treat those exposed with preventive antibiotics? Our model provides real answers to help policy makers when they need that information."

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our bio-terrorism / terrorism section for the latest news on this subject.

Toth DJA, Gundlapalli AV, Schell WA, Bulmahn K, Walton TE, et al. (2013) Quantitative Models of the Dose-Response and Time Course of Inhalational Anthrax in Humans. PLoS Pathog 9(8): e1003555. doi:10.1371/journal.ppat.1003555

University of Utah Health Sciences

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

University of Utah Health Sciences. "Mathematical model makes defensible estimates of how scenarios might play out if anthrax were released in a terrorist attack." Medical News Today. MediLexicon, Intl., 19 Aug. 2013. Web.
19 Aug. 2013. APA
University of Utah Health Sciences. (2013, August 19). "Mathematical model makes defensible estimates of how scenarios might play out if anthrax were released in a terrorist attack." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/264944.php.

Please note: If no author information is provided, the source is cited instead.


'Mathematical model makes defensible estimates of how scenarios might play out if anthrax were released in a terrorist attack'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam). We reserve the right to amend opinions where we deem necessary.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Tuesday, 30 July 2013

High platelet reactivity on clopidogrel predicts stent thrombosis, heart attack, and bleeding

Main Category: Cardiovascular / Cardiology
Also Included In: Medical Devices / Diagnostics;  Blood / Hematology
Article Date: 30 Jul 2013 - 0:00 PDT Current ratings for:
High platelet reactivity on clopidogrel predicts stent thrombosis, heart attack, and bleeding
not yet ratednot yet rated

Patients who receive a drug-eluting stent (DES) and demonstrate high platelet reactivity on clopidogrel are more likely to have blood clots form on the stent and to suffer a heart attack; however, these patients are less likely to develop bleeding complications. One-year results of the ADAPT-DES trial was published online in The Lancet. The findings were first presented at last year's Transcatheter Cardiovascular Therapeutics (TCT) annual scientific symposium.

ADAPT-DES is the largest study ever to explore the overall treatment implications of platelet reactivity on patient outcomes after successful coronary drug-eluting stent implantation. Researchers investigated the relationship between platelet reactivity during dual therapy with aspirin and clopidogrel and clinical outcomes such as stent thrombosis, major bleeding, and other adverse events.

The study enrolled 8,583 patients at 11 sites in the US and Germany who underwent a percutaneous coronary intervention (PCI) with at least one drug-eluting stent between January 7, 2008, and September 16, 2010. Researchers assessed platelet reactivity with the VerifyNow Aspirin, P2Y12, and IIb/IIIa tests. Patients were followed for one year to determine the relationship between platelet reactivity and subsequent events. At one year, stent thrombosis had occurred in 70 patients (0.8 percent), heart attack in 269 (3.1 percent), major bleeding in 531 (6.2 percent), and death in 161 (1.9 percent).

Platelet reactivity units (PRU), an index of platelet inhibition to clopidogrel, were measured by the VerifyNow P2Y12 test. High platelet reactivity, defined as a PRU of greater than 208, was present in 42.7 percent of patients. At one year, researchers found that high platelet reactivity was significantly associated with stent thrombosis (1.3 percent vs. 0.5 percent) and heart attack (3.9 percent vs. 2.7 percent), but was also found to be protective against major bleeding (5.6 percent vs. 6.7 percent). High platelet reactivity was also associated with one-year mortality (2.4 percent vs. 1.5 percent). However, because high platelet reactivity is also associated with other patient risk factors and baseline characteristics, multivariable modeling was also performed; it showed no independent association between high platelet reactivity and mortality.

"Results from the ADAPT-DES registry definitely demonstrate that high platelet reactivity after implantation of drug-eluting stents is an independent predictor of one-year stent thrombosis and heart attack, but it is also protective against major bleeding, both of which impact mortality," said lead investigator Gregg W. Stone, MD. Dr Stone is professor of medicine at Columbia University College of Physicians and Surgeons and Director of Cardiovascular Research and Education at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center. Dr. Stone is also co-director of the Medical Research and Education Division at the Cardiovascular Research Foundation (CRF).

"Because of the counteracting effects of ischemia and bleeding, platelet reactivity was not an independent predictor of one-year mortality. Therefore, overcoming high platelet reactivity with more potent antiplatelet agents is unlikely to improve survival unless the beneficial effect of reducing stent thrombosis and heart attack can be separated from the likely increase in bleeding that results from greater platelet inhibition," said Dr. Stone.

Dr. Stone added: "Platelet reactivity on aspirin was unrelated to stent thrombosis, heart attack, or death, but may be related to bleeding. This raises questions as to the utility of aspirin in patients treated with drug-eluting stents."

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our cardiovascular / cardiology section for the latest news on this subject.

The ADAPT-DES trial was sponsored by CRF with research support from Boston Scientific, Abbott Vascular, Medtronic, Cordis, Biosensors, The Medicines Company, Daiichi Sankyo, Eli Lilly, Volcano, and Accumetrics.

Cardiovascular Research Foundation

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Foundation, Cardiovascular Research. "High platelet reactivity on clopidogrel predicts stent thrombosis, heart attack, and bleeding." Medical News Today. MediLexicon, Intl., 30 Jul. 2013. Web.
30 Jul. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'High platelet reactivity on clopidogrel predicts stent thrombosis, heart attack, and bleeding'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam). We reserve the right to amend opinions where we deem necessary.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Wednesday, 24 July 2013

Health Tips & Info : Classification Of Myocardial Infarction (MI) Or Heart Attack.


Transmural : associated with atherosclerosis involving major coronary artery. It can be subclassified into anterior, posterior, inferior, lateral or septal. Transmural infarcts extend through the whole thickness of the heart muscle and are usually a result of complete occlusion of the area's blood supply.Subendocardial : involving a small area in the subendocardial wall of the left ventricle, ventricular septum, or papillary muscles. Subendocardial infarcts are thought to be a result of locally decreased blood supply, possibly from a narrowing of the coronary arteries. The subendocardial area is farthest from the heart's blood supply and is more susceptible to this type of pathology.Clinically, a myocardial infarction can be further subclassified into a ST elevation MI (STEMI) versus a non-ST elevation MI (non-STEMI) based on ECG changes.The phrase "heart attack" is sometimes used incorrectly to describe sudden cardiac death, which may or may not be the result of acute myocardial infarction. A heart attack is different from, but can be the cause of cardiac arrest, which is the stopping of the heartbeat, and cardiac arrhythmia, an abnormal heartbeat. It is also distinct from heart failure, in which the pumping action of the heart is impaired; severe myocardial infarction may lead to heart failure, but not necessarily.A 2007 consensus document classifies myocardial infarction into five main types:Type 1 – Spontaneous myocardial infarction related to ischaemia due to a primary coronary event such as plaque erosion and/or rupture, fissuring, or dissection.Type 2 – Myocardial infarction secondary to ischaemia due to either increased oxygen demand or decreased supply, e.g. coronary artery spasm, coronary embolism, anaemia, arrhythmias, hypertension, or hypotension.Type 3 – Sudden unexpected cardiac death, including cardiac arrest, often with symptoms suggestive of myocardial ischaemia, accompanied by presumably new ST elevation, or new LBBB, or evidence of fresh thrombus in a coronary artery by angiography and/or at autopsy, but death occurring before blood samples could be obtained, or at a time before the appearance of cardiac biomarkers in the blood.Type 4 – Associated with coronary angioplasty or stents:Type 4a – Myocardial infarction associated with PCI.Type 4b – Myocardial infarction associated with stent thrombosis as documented by angiography or at autopsy.Type 5 – Myocardial infarction associated with CABG.

View the original article here

Health Tips & Info : Panic Attack and Panic Disorder Medicines.


When situation becomes too difficult to handle in case of a panic disorder patient, medication comes to play a significant role. Various medications can reduce and control the panic attacks and panic disorder in patients. However, other natural ways along with usage of medicines prove truly helpful while resolving such disorders. Medication proves to be much effective if combined with various therapies and other lifestyle change techniques.Medical professionals advise various antidepressants for treating panic disorders and panic attacks. But, this treatment is of a quite long duration as it continues for several weeks and therefore needs to be carried out continuously. In such scenarios, the patients are advised not to stop the medicine usage and continue using the prescribed ones even if there isn’t any repetitive panic attack.Doctors usually advise Benzodiazepines, which are anti-anxiety drugs and have rapid effects on the body during panic attacks and panic disorders. Consumption of these drugs provides a lot of relief from the panic attack symptoms. The only drawback of such medicines is that these are very addictive in nature and come with serious withdrawal symptoms. Therefore, they are advised and used with extra care and precaution.

View the original article here